Tacrolimus Monotherapy in Liver Transplantation: One-Year Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Background:Minimal immunosuppression (IS) is desirable in organ transplantation to reduce side effects and to promote the process of tolerance induction. Material and Methods:Between February 2000 and September 2004, 156 adults (>15 years old) receiving a primary liver graft were enrolled in a prospective, randomized, double-blind, placebo-controlled, investigator-driven single-center study comparing tacrolimus (TAC)-placebo (PL) and TAC-low-dose, short-term (64 days) steroid (ST) IS. There were no exclusion criteria at moment of randomization. All patients had a 12-month follow-up (range, 12–84). Results:Three- and 12-month patient survival rates were 93.6% and 87.2% in the TAC-PL group and 98.7% and 94.7% in TAC-ST group (P = 0.096 and P = 0.093, respectively). Three- and 12-month graft survival rates were 92.3% and 85.9% versus 97.4% and 92.3% (P = 0.14 and 0.13, respectively). By 3 and 12 months, rejection treatment had been given in 20.5% (16 pts) and 23% (18 pts) of TAC-PL patients and in 12.7% (10 pts) and 20.5% (16 pts) of TAC-ST patients (P = 0.20 and 0.54). Corticosteroid-resistant rejection (CRR) at 3 and 12 months was recorded in 12.8% (10 pts) of TAC-PL patients and 3.8% (3 pts) of TAC-ST patients (P = 0.04). When considering the 145 patients transplanted without artificial organ support (n = 145), CRR at 3 and 12 months was recorded in 8.8% (6/68 pts) of TAC-PL patients and in 3.9% (3/77 pts) of TAC-ST patients (P = 0.22). Vanishing bile duct syndrome was diagnosed in 1 (1.2%) TAC-PL patient and 4 (5.1%) TAC-ST patients (P = 0.17). By 1 year, 78.2% (61/78) of TAC-PL patients and 82% (64/78) of TAC-ST patients were on TAC monotherapy (P = 0.54). When considering 67 TAC-PL and 74 TAC-ST survivors, rates of monotherapy were 91% (61 pts) and 86.5% (64 pts) (P = 0.39). At 1 year, 62.5% (42 pts) of TAC-PL survivors and 64.9% (48 pts) of TAC-ST survivors were on low-dosage (<6 ng/mL) TAC monotherapy (P 0.79). Conclusion:TAC monotherapy can be achieved safely without compromising graft nor patient survival in a primary, even unselected, adult liver transplant population. The higher incidence of early CRR in the TAC-PL group related to the significantly higher number of patients transplanted while being on artificial organ support. In such condition, this monodrug immunosuppressive strategy needs to be adapted. TAC monotherapy strategy should lay the basis for further large scale minimization studies in liver transplantation.

[1]  U. Neumann,et al.  CMV hepatitis after liver transplantation: Incidence, clinical course, and long‐term follow‐up , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  Y. Takeda,et al.  Steroid-free living-donor liver transplantation in adults. , 2005, Transplantation.

[3]  A. Sheil,et al.  A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts. , 2001, Transplantation.

[4]  B. Davidson,et al.  A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. , 1999, Transplantation.

[5]  R. Malthaner,et al.  Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  R. Rubin,et al.  The prevention of infection post‐transplant: the role of prophylaxis, preemptive and empiric therapy , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  M. Hart,et al.  Blood and graft eosinophilia as predictors of rejection in human liver transplantation. , 1989, Transplantation.

[8]  S. Negrini,et al.  A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. , 1999, Transplantation.

[9]  T. Starzl,et al.  THROMBOCYTOPENIA IN LIVER TRANSPLANT RECIPIENTS , 2000 .

[10]  I. Bilbao,et al.  A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[11]  S. Fan,et al.  Interleukin‐2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  D. Eckhoff,et al.  Two-dose Daclizumab Induction Therapy in 209 Liver Transplants: A Single-Center Analysis , 2004, Transplantation.

[13]  J. Fung,et al.  Liver transplant tolerance: Mechanistic insights from animal models, with particular reference to the mouse , 1997 .

[14]  A. Sánchez‐Fueyo,et al.  An Appraisal of Tolerance in Liver Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  W. Bechstein,et al.  Steroid withdrawal after pediatric liver transplantation: a long-term follow-up study in 109 recipients. , 2003, Transplantation.

[16]  R. Reding.  STEROID WITHDRAWAL IN LIVER TRANSPLANTATION , 2000 .

[17]  M. O’Connor,et al.  Thrombocytopenia after liver transplantation. , 1988, Transplantation proceedings.

[18]  A. Cohen,et al.  Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1 , 2003, Transplantation.

[19]  A. Dhillon,et al.  Histological patterns of rejection using oral microemulsified cyclosporine and tacrolimus (FK506) as monotherapy induction after orthotopic liver transplantation. , 2001, Liver.

[20]  J. Figueras,et al.  Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. , 2006, Journal of hepatology.

[21]  A. Dhillon,et al.  Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[22]  T. Starzl,et al.  Transplantation tolerance from a historical perspective , 2001, Nature Reviews Immunology.

[23]  E. Sokal,et al.  Steroid-free liver transplantation in children , 2003, The Lancet.

[24]  D. Elbourne,et al.  Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial , 2002, The Lancet.

[25]  A. Dhillon,et al.  Applications and Limitations of Blood Eosinophilia for the Diagnosis of Acute Cellular Rejection in Liver Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  A. Louvel,et al.  Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients. , 1995, Transplantation.

[27]  R. Wiesner,et al.  Update of the International Banff Schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection , 2000, Hepatology.

[28]  T A Louis,et al.  A meta-analysis of immunosuppression withdrawal trials in renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[29]  S. Karademir,et al.  Seventh Day Syndrome--acute hepatocyte apoptosis associated with a unique syndrome of graft loss following liver transplantation. , 2001, Liver.

[30]  T. Starzl,et al.  Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus , 2004, Transplantation.

[31]  J. Neuberger,et al.  Steroid withdrawal from long-term immunosuppression in liver allograft recipients. , 1993, Transplantation.

[32]  M. Masetti,et al.  Preliminary Results of a “Prope” Tolerogenic Regimen with Thymoglobulin Pretreatment and Hepatitis C Virus Recurrence in Liver Transplantation , 2005, Transplantation.

[33]  J. Neuberger,et al.  What is the significance of acute liver allograft rejection? , 1998, Journal of hepatology.

[34]  M. Rieder,et al.  Pretreatment with Glucocorticoids Enhances T-Cell Effector Function: Possible Implication for Immune Rebound Accompanying Glucocorticoid Withdrawal , 1999, Cell transplantation.

[35]  F. Callea,et al.  Double-Blind Comparison of Hepatitis C Histological Recurrence Rate in HCV+ Liver Transplant Recipients Given Basiliximab+Steroids or Basiliximab+Placebo, in addition to Cyclosporine and Azathioprine , 2004, Transplantation.

[36]  I. Marino,et al.  Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. , 2006, The Journal of surgical research.

[37]  J. Neuberger,et al.  Massive haemorrhagic necrosis of the liver after liver transplantation. , 1989, Journal of clinical pathology.

[38]  G Otto,et al.  Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double‐Blinded Placebo‐Controlled Trial , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  D. Hricik,et al.  Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. , 1993, Journal of the American Society of Nephrology : JASN.

[40]  J. Figueras,et al.  Daclizumab induction and maintenance steroid‐free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[41]  J. Barkun,et al.  Early steroid withdrawal after liver transplantation: The canadian tacrolimus versus microemulsion cyclosporin a trial: 1‐year follow‐up , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[42]  R. Reding.  Steroid withdrawal in liver transplantation: benefits, risks, and unanswered questions. , 2000, Transplantation.

[43]  C. Margarit,et al.  Corticosteroid‐free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[44]  D. Samuel,et al.  Steroid withdrawal at day 14 after liver transplantation: A double‐blind, placebo‐controlled study , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[45]  Randall G. Lee,et al.  Banff schema for grading liver allograft rejection: An international consensus document , 1997, Hepatology.

[46]  N. Sinclair,et al.  Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[47]  R. Lechler,et al.  From current immunosuppressive strategies to clinical tolerance of allografts , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[48]  S. Nishida,et al.  Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation , 2003, Transplantation.

[49]  P. Burra,et al.  Quality of life following organ transplantation , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[50]  O. Ciccarelli,et al.  Cavocaval adult liver transplantation and retransplantation without venovenous bypass and without portocaval shunting: a prospective feasibility study in adult liver transplantation , 2003, Transplantation.

[51]  Paulo Fontes,et al.  Tolerogenic immunosuppression for organ transplantation , 2003, The Lancet.

[52]  O. Ciccarelli,et al.  Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression – 5 year results of a prospective study , 2001, Transplant international : official journal of the European Society for Organ Transplantation.

[53]  Nina Singh,et al.  Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin. , 2000, Transplantation.

[54]  A. Dhillon,et al.  Eosinophils in acute cellular rejection in liver allografts. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.